Board of Directors
Blackstone Life Sciences
Dennis Henner is an Operating Partner in Blackstone Life Sciences group, having joined Blackstone as part of its acquisition of Clarus in December of 2018.
Prior to joining Blackstone, he was co-founder and Managing Director of Clarus for 12 years beginning in 2005 with the firm’s inception. Dr. Henner has over 30 years of direct industry and investment experience within the healthcare sector and has led investments in the biopharmaceutical sector including partnerships with pharmaceutical companies. Prior to Clarus, Dr. Henner was a General Partner at MPM Capital, a healthcare venture capital firm. From 1981 to 2001, he was an executive at Genentech where he held various positions including Senior Vice President of Research and was a member of Genentech’s executive committee. Dr. Henner is currently a member of the Board of Directors for Forty Seven Inc. (NASDAQ: FTSV) and Imago BioSciences.
Dr. Henner received his PhD from the Department of Microbiology at the University of Virginia and did postgraduate training at the Scripps Clinic and Research Foundation. Dr. Henner is a member of the Board of Trustees of Reed College.
Managing General Partner
Frazier Healthcare Partners
Patrick has successfully partnered with entrepreneurs across a range of company types and stages, from early-stage anti-infectives companies to >$100M commercial-stage dermatology companies. Patrick has also been active in company formation around both early- and later-stage assets. He has led and served as director for many successful Frazier Life Sciences investments., He currently serves on the boards of Amunix, Imago BioSciences, Iterum Therapeutics (NASDAQ: ITRM), Mirum Pharmaceuticals, Passage Bio, ScoutBio, Silvergate Pharmaceuticals and SutroVax.
Prior to joining Frazier, Patrick helped develop McKinsey & Company’s West Coast biotechnology consulting practice, where he led projects involving mergers and acquisitions, product launches, sales force optimization, corporate partnering, and research prioritization.
Patrick holds a B.A. from the University of North Carolina at Chapel Hill, where he is a Phi Beta Kappa graduate and Morehead Scholar. He received his M.B.A. from Harvard Business School.
Dr. Alan Sachs
Chief Scientific Officer
Thermo Fisher Scientific.
Dr. Sachs leads efforts to help customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. He served as the Chief Scientific Officer for Life Technologies and Life Sciences Solutions Group within Thermo Fisher between 2012 and 2015.
Prior to this role, Dr. Sachs was the Vice President of Exploratory and Translational Sciences at Merck Research Laboratories. During his ten years at Merck, he built and directed the global RNA Therapeutics Department, led the Rosetta Inpharmatics group, and led the Department of Molecular Profiling.
Before joining Merck, Dr. Sachs was an Associate Professor of Molecular and Cell Biology at the University of California at Berkeley, and a Whitehead Institute Fellow at the Whitehead Institute. Dr. Sachs graduated from Cornell University with a B.A. in Biochemistry, and from Stanford Medical School with an M.D, a Ph.D. with Roger Kornberg, and post-doctoral research with Ron Davis. Dr. Sachs serves on the Board of Directors for Imago BioSciences and the Advisory Board for The Bakar Fellows at University of California, Berkeley.
Dr. Dina Chaya, Ph.D.
Dr. Chaya has been investing in the private equity and venture capital healthcare industry since 2001previously at 3i in London and Index Ventures in Geneva. Previous investments include Wilson Therapeutics, EUSA Pharma, Endosense and Novexel. She currently serves on the Board of Directors of Imago BioSciences, Oxular, and TopiVert.
Dina is a member of the Venture Capital Platform Council of Invest Europe. She is a CFA charterholder and holds a Ph.D. degree in Molecular and Cellular Biology from Paris VI University, France. She also carried out postdoctoral research at Brown University, Providence, US, and at the Fox Chase Cancer Centre, Philadelphia, US.